DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
KRYS Krystal Biotech Inc
HSV-1 gene therapy platform moves from skin to lung: robust CFTR expression in CF lungs, repeat dosing on deck, and JPM 2026 as the launchpad for a mutation-agnostic CF strategy.
SPACE & DEFENCE 2026
SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day.
OMER The Plan
DA approval is in the bag, pricing is out in the open, and the call with transplant KOLs was basically a long “here’s how we want to own TA-TMA”. Let’s unpack what Omeros is really trying to do with YARTEMLEA, beyond the usual headline noise.
RNXT RenovoRx Inc UPDATED jan 9
Micro-cap (~37M $) clinical/commercial biotech developing a targeted drug-device platform (TAMP + RenovoCath) for solid tumors, with a pivotal Phase 3 trial in locally advanced pancreatic cancer (TIGeR-PaC) and a near-term catalyst at ASCO GI 2026
KODK Eastman Kodak Co
KODK – Turnaround / Advanced Materials Deep Dive | Merlintrader trading Blog KODK (KODK) – TURNAROUND / ADVANCED MATERIALS & CHEMICALS Mid-cap industrial (≈$800M) in full transition: from legacy photography to commercial print, advanced materials & chemicals, EV battery electrodes…
KOD Kodiak Sciences Inc
After a brutal Phase 3 failure in diabetic macular edema (DME) and years of being treated as a write-off, Kodiak is back on catalyst watch thanks to strong GLOW1 data in diabetic retinopathy (DR), a fully enrolled confirmatory Phase 3 GLOW2 study and the ongoing DAYBREAK trial in wet AMD. All patients in GLOW2 are expected to complete their primary endpoint visit by the end of January 2026, with topline data guided for the first quarter of 2026. For a name that has historically moved violently on news, this is a critical “reboot or bust” window.
DRUG Bright Minds Biosciences
On January 6, 2026, Bright Minds reported positive topline results from its open-label Phase 2 BREAKTHROUGH study of BMB-101 in adults with drug-resistant absence seizures and developmental and encephalopathic epilepsies (DEE)
ACRV Acrivon Therapeutics Inc
Clinical-stage precision oncology small cap (~170–190M $) built around the AP3 predictive phosphoproteomics platform, advancing ACR-368 in registrational-intent Phase 2b (with planned confirmatory Phase 3) and ACR-2316, a dual WEE1/PKMYT1 inhibitor, with fresh data coming at the January 8, 2026 webcast
OMER Omeros Corp 2026
After years of being treated as a “show-me story”, Omeros enters 2026 with two key green lights: FDA approval of Yartemlea (narsoplimab-wuug) and a large strategic deal with Novo Nordisk on OMS906. This report walks through the approval process, current US/EU regulatory status, the financial impact of the Novo deal, and a catalyst map for 2026.
NRXP and the Phantom PDUFA 2
Over the last 18–24 months, NRx Pharmaceuticals (NRXP) has built a storyline around NRX-100 (preservative-free IV ketamine) that many retail traders translated into a simple, crisp line: “PDUFA by year-end 2025.”
IBIO iBio Inc
iBio (IBIO) has turned into a small but noisy name in the obesity-drug corner of biotech. It’s a micro-cap (~42–45M $) that has radically repositioned itself as an AI-driven antibody company for obesity and cardiometabolic disease, with a clear—if high-risk—angle: “post-GLP-1” biology focused on Activin E, myostatin/Activin A and the amylin receptor.
NBIX Neurocrine Biosciences, Inc
Companion EN/IT deep dive on Neurocrine Biosciences: INGREZZA as the main cash engine in movement disorders, CRENESSITY as the first new therapy for classic CAH in 70 years, and an expanding psychiatry pipeline (NBI-1117568 and related muscarinic programmes). Focus on 2025–2026 catalysts, risk map and how NBIX fits in a catalyst-driven biotech watchlist.
INCY Incyte Corp
Incyte is a classic mid-cap biotech with a single dominant product (Jakafi) and a long history of oncology R&D. After several high-profile pipeline disappointments, the company has shifted from aggressive expansion to a more selective, risk-controlled development strategy.
VRTX Vertex Pharmaceuticals- CRISPR-Therapeutics
ASGEVY hits primary endpoints in children 5–11 with SCD and TDT – global paediatric filings planned for 1H 2026
Context: ASH 2025 & pre-JPM 2026 – CLIMB-151 (SCD) and CLIMB-141 (TDT) paediatric cohorts (5–11 years).
Vertex has presented the first pivotal data for CASGEVY in children aged 5–11 with sickle cell disease and transfusion-dependent beta-thalassemia. In both Phase 3 trials, all evaluable patients with sufficient follow-up achieved the primary endpoints (absence of vaso-occlusive crises for SCD; sustained transfusion independence for TDT) with VOC-free and transfusion-free periods approaching two years in some cases. Safety so far remains consistent with the adult programme.
JPM Healthcare Conference 2026
The 44th Annual J.P. Morgan Healthcare Conference is widely considered the most influential healthcare investment meeting in the world. Often described as the “Super Bowl of Healthcare”, it brings together more than 8,000 participants, including C-suite executives, institutional investors, policymakers, analysts and media.
KALA Kala Bio Inc
Deep dive on KALA BIO after the CHASE Phase 2b collapse, the Oxford Finance default, David Lazar’s $6M rescue, and the December 26, 2025 completion of the $2M debt settlement that wipes out ~$10.6M in obligations.
AUPH Aurinia Pharmaceuticals Inc
AUPH has been on every biotech retail watchlist since the January 22, 2021 FDA approval of LUPKYNIS (voclosporin) for lupus nephritis. The buyout never came, but the company did the one thing that really matters: it built a profitable, growing LN franchise.
TARA Protara Therapeutics Inc
Key message: the FDA has granted Breakthrough Therapy and Fast Track designations to TARA-002 for the treatment of pediatric macrocystic and mixed cystic lymphatic malformations (LMs), on top of the existing Rare Pediatric Disease designation and inclusion in the FDA’s CMC Development and Readiness Pilot program.
This turns TARA-002 into a rare triple-designation asset in a high-need pediatric space, and gives Protara a clearly accelerated regulatory lane while the stock is still trading in single digits.
ALT Altimmune
Key message: the FDA has granted Breakthrough Therapy Designation (BTD) to pemvidutide for the treatment of MASH, based on 24-week data from the Phase 2b IMPACT trial (company press release, Jan 5 2026 and IMPACT publication).
The stock immediately reacts with an intraday move around +15–20% (as reported by outlets like Seeking Alpha and Investing.com). This is not a random bounce, it is a repricing of regulatory risk.
Weekly Recap and next week outlook dec 29-jan 02 jan 05-jan 09
From PDUFA shocks to early 2026 catalysts: what just happened and what traders should watch next week.